Larvol Delta - On-track-to-submit-Conditional-Marketing-Authorization-for-iopofosine-I-131-to-European-Medicines-Agency-in-Q3-2026-for-potential-2027-EU-commercialization-as-a-treatment-for-Waldenstr246m-Macroglobulinemia

iopofosine I-131 (CLR 131) - Cellectar

https://www.globenewswire.com/fr/news-release/2026/03/04/3249235/0/en/Cellectar-Biosciences-Reports-Financial-Results-for-Year-Ended-2025-and-Provides-Corporate-Updates.html

Mar 4, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next